Treatment of Discoid Lupus Erythematosus with Severe or Widespread Skin Lesions

When discoid lupus erythematosus presents with severe or extensive cutaneous involvement, standard topical management is often insufficient. This protocol covers the systemic approach for patients in this higher-risk setting.

Clinical scenario: Severe or widespread active skin lesions of discoid lupus erythematosus, with risk of scarring or progression to systemic disease, in patients who are not pregnant and not breastfeeding.

Treatment approach: Management in this setting involves thalidomide, used preferably in combination with antimalarials. The complete structured protocol — including the full sequencing, tapering guidance, and monitoring requirements — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
We recommend thalidomide for selected refractory CLE patients, preferably in addition to antimalarials.
We suggest a starting dose of 100 mg per day and, after clinical effectiveness, to taper to a minimum dose.

View source ↗